These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27400895)

  • 1. The Birth, and Evolution, of Percutaneous Coronary Interventions: A Conversation With Patrick Serruys, MD, PhD.
    Serruys PW; Rutherford JD
    Circulation; 2016 Jul; 134(2):97-100. PubMed ID: 27400895
    [No Abstract]   [Full Text] [Related]  

  • 2. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of various percutaneous interventions for in-stent restenosis: comprehensive network meta-analysis of randomized controlled trials.
    Sethi A; Malhotra G; Singh S; Singh PP; Khosla S
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002778. PubMed ID: 26546577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of drug-eluting stents for the treatment of coronary chronic total occlusions.
    Brilakis ES; Kotsia A; Luna M; Garcia S; Abdullah SM; Banerjee S
    Expert Rev Cardiovasc Ther; 2013 Oct; 11(10):1349-58. PubMed ID: 24138522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary artery aneurysms formation within Everolimus-eluting stents and bioresorbable vascular scaffolds.
    Lee WC; Chung WJ; Fang HY; Wu CJ
    Int J Cardiol; 2016 Mar; 206():58-60. PubMed ID: 26774833
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug-eluting versus bare-metal coronary stents: where are we now?
    Amoroso NS; Bangalore S
    J Comp Eff Res; 2012 Nov; 1(6):501-8. PubMed ID: 24236469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 40 Years on.
    Emmert MY; Templin C
    Eur Heart J; 2017 Jul; 38(28):2158-2160. PubMed ID: 28838046
    [No Abstract]   [Full Text] [Related]  

  • 8. Dexamethasone-eluting vascular stents.
    Hämäläinen M; Nieminen R; Uurto I; Salenius JP; Kellomäki M; Mikkonen J; Kotsar A; Isotalo T; Teuvo Tammela LJ; Talja M; Moilanen E
    Basic Clin Pharmacol Toxicol; 2013 May; 112(5):296-301. PubMed ID: 23374962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial.
    Kereiakes DJ; Meredith IT; Windecker S; Lee Jobe R; Mehta SR; Sarembock IJ; Feldman RL; Stein B; Dubois C; Grady T; Saito S; Kimura T; Christen T; Allocco DJ; Dawkins KD
    Circ Cardiovasc Interv; 2015 Apr; 8(4):. PubMed ID: 25855680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effect of second-generation drug-eluting stents for coronary artery disease, everolimus-eluting versus zotarolimus-eluting stents: a meta-analysis.
    Qi-Hua L; Qi Z; Yu Z; Xiao-Long L; Hai-Gang J; Jian-Feng Y; Yi S
    Coron Artery Dis; 2015 May; 26(3):259-65. PubMed ID: 25715339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-eluting stents.
    Whitlow P
    J Invasive Cardiol; 2004 Jul; 16(7 Suppl):2S-6S. PubMed ID: 23573564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
    Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial.
    Natsuaki M; Kozuma K; Morimoto T; Kadota K; Muramatsu T; Nakagawa Y; Akasaka T; Igarashi K; Tanabe K; Morino Y; Ishikawa T; Nishikawa H; Awata M; Abe M; Okada H; Takatsu Y; Ogata N; Kimura K; Urasawa K; Tarutani Y; Shiode N; Kimura T
    Circ Cardiovasc Interv; 2015 Oct; 8(10):. PubMed ID: 26446596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Did Andreas Get Here?
    King SB
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1645-6. PubMed ID: 26493260
    [No Abstract]   [Full Text] [Related]  

  • 15. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods.
    Serruys PW; Ormiston JA; Onuma Y; Regar E; Gonzalo N; Garcia-Garcia HM; Nieman K; Bruining N; Dorange C; Miquel-Hébert K; Veldhof S; Webster M; Thuesen L; Dudek D
    Lancet; 2009 Mar; 373(9667):897-910. PubMed ID: 19286089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edge vascular response after percutaneous coronary intervention: an intracoronary ultrasound and optical coherence tomography appraisal: from radioactive platforms to first- and second-generation drug-eluting stents and bioresorbable scaffolds.
    Gogas BD; Garcia-Garcia HM; Onuma Y; Muramatsu T; Farooq V; Bourantas CV; Serruys PW
    JACC Cardiovasc Interv; 2013 Mar; 6(3):211-21. PubMed ID: 23517830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metal allergy to everolimus-eluting cobalt chromium stents confirmed by positive skin testing as a cause of recurrent multivessel in-stent restenosis.
    Nakajima Y; Itoh T; Morino Y
    Catheter Cardiovasc Interv; 2016 Mar; 87(4):E137-42. PubMed ID: 26011018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and study design of the RESERVOIR trial: a randomized trial comparing reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus.
    Romaguera R; Brugaletta S; Gomez-Lara J; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Gómez-Hospital JA; Montanya E; Alfonso F; Valgimigli M; Sabate M; Cequier A
    Catheter Cardiovasc Interv; 2015 Mar; 85(4):E116-22. PubMed ID: 25380051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interventional cardiology: Operator technique is predictive of BVS-related adverse events.
    Huynh K
    Nat Rev Cardiol; 2018 Feb; 15(2):67. PubMed ID: 29263446
    [No Abstract]   [Full Text] [Related]  

  • 20. The first PTCAs in Zurich, in 1977.
    Turina M
    Eur Heart J; 2017 Jul; 38(28):2166-2167. PubMed ID: 28838049
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.